Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -37.63% is 22% above its 5-year average of -48.17%, near the high end of its 5-year range (-100.46%–-22.03%).
31.77% above its 12-month average of -55.16%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -13.11%.
RETURN ON ASSETS (ROA)
-37.63%
RETURN ON ASSETS (ROA) AVG TTM
-55.16%
RETURN ON ASSETS (ROA) AVG 3Y
-41.63%
RETURN ON ASSETS (ROA) AVG 5Y
-48.17%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+31.77%
CURRENT VS 3Y AVG
+9.60%
CURRENT VS 5Y AVG
+21.88%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.02%
median of 565 covered companies
CURRENT VS SECTOR MEDIAN
-34.30%
vs the sector median at left
Aura Biosciences, Inc.
Market Cap
$638.20M
Return on Assets (ROA)
-37.63%
TTM Avg
-55.16%
3Y Avg
-41.63%
5Y Avg
-48.17%
Market Cap
$649.13M
Return on Assets (ROA)
-36.37%
TTM Avg
-26.71%
3Y Avg
-31.04%
5Y Avg
-27.33%
Market Cap
$625.03M
Return on Assets (ROA)
-23.40%
TTM Avg
-34.85%
3Y Avg
-33.75%
5Y Avg
-41.05%
Market Cap
$621.12M
Return on Assets (ROA)
-7.75%
TTM Avg
-4.25%
3Y Avg
-2.93%
5Y Avg
9.76%
Market Cap
$620.40M
Return on Assets (ROA)
-13.75%
TTM Avg
-12.94%
3Y Avg
-23.44%
5Y Avg
-17.36%
Market Cap
$658.52M
Return on Assets (ROA)
-70.67%
TTM Avg
-51.05%
3Y Avg
-54.02%
5Y Avg
-55.25%
Market Cap
$665.25M
Return on Assets (ROA)
-82.36%
TTM Avg
-56.97%
3Y Avg
-52.21%
5Y Avg
-45.34%
Market Cap
$666.85M
Return on Assets (ROA)
2.22%
TTM Avg
15.13%
3Y Avg
10.21%
5Y Avg
1.65%
Market Cap
$598.37M
Return on Assets (ROA)
45.55%
TTM Avg
3.15%
3Y Avg
-47.64%
5Y Avg
-20.78%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aura Biosciences, Inc. (AURA) | $638.20M | -37.63% | -55.16% | -41.63% | -48.17% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $649.13M | -36.37% | -26.71% | -31.04% | -27.33% |
| Climb Bio, Inc. (CLYM)vs › | $625.03M | -23.40% | -34.85% | -33.75% | -41.05% |
| Fulgent Genetics, Inc. (FLGT)vs › | $621.12M | -7.75% | -4.25% | -2.93% | 9.76% |
| AngioDynamics, Inc. (ANGO)vs › | $620.40M | -13.75% | -12.94% | -23.44% | -17.36% |
| Helus Pharma Inc. (HELP)vs › | $658.52M | -70.67% | -51.05% | -54.02% | -55.25% |
| Annexon, Inc. (ANNX)vs › | $665.25M | -82.36% | -56.97% | -52.21% | -45.34% |
| MiMedx Group, Inc. (MDXG)vs › | $666.85M | 2.22% | 15.13% | 10.21% | 1.65% |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $598.37M | 45.55% | 3.15% | -47.64% | -20.78% |
| Faeth Therapeutics, Inc. (FTH)vs › | $683.14M | -103.29% | -79.28% | -61.36% | -60.54% |
ROA
-37.6%
ROE
-41.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -62.68% |
| 2024-12-31 | -47.63% |
| 2023-12-31 | -29.96% |
| 2022-12-31 | -26.24% |
| 2021-12-31 | -22.03% |
| 2020-12-31 | -100.46% |
| 2019-12-31 | -65.31% |
